Drugs

, Volume 75, Issue 1, pp 75–82 | Cite as

Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer

Adis Drug Evaluation
Part of the following topical collections:
  1. Topical Collection on Lung Cancer

Abstract

Alectinib (Alecensa®) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan drug designation. Approval was based on a phase 1–2 study in ALK inhibitor-naive patients with ALK-rearranged advanced NSCLC who received twice-daily alectinib 300 mg. In the phase 2 portion, 93.5 % of patients achieved an objective response. Treatment response was rapid, with a partial response achieved in two-thirds of patients within 3 weeks (cycle 1). Patient follow-up is ongoing, and after approximately 2 years, 19.6 % of patients had achieved a complete response, and the 2-year progression-free survival rate is 76 %. During treatment with alectinib (median follow-up approximately 8 months), there was no progression of CNS lesions among patients with known CNS metastases at baseline (although prior radiation therapy may have confounded results). In preclinical models, alectinib was active against most ALK fusion-gene mutations related to crizotinib resistance, and preliminary results from clinical trials indicate efficacy in crizotinib-refractory NSCLC. Alectinib was generally well tolerated in clinical trials, and there were no treatment-related grade 4 adverse events or deaths. The most common grade 3 treatment-related adverse events were decreased neutrophil counts and increased creatinine phosphokinase. While more data are needed to confirm the efficacy of alectinib and to evaluate its activity in crizotinib-resistant disease, the drug provides a very promising option for the treatment of ALK-rearranged advanced NSCLC.

Keywords

Epidermal Growth Factor Receptor Objective Response Rate Epidermal Growth Factor Receptor Mutation Anaplastic Lymphoma Kinase Anaplastic Large Cell Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. Kate McKeage is salaried employee of Adis/Springer. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2014 [online]. http://www.cancer.org/acs. Accessed 2014 Aug 12.
  2. 2.
    D’Arcangelo M, Wynes MW, Hirsch FR. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 2013;25(2):121–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Cole P. Alectinib hydrochloride: ALK receptor tyrosine kinase inhibitor oncolytic. Drugs Future. 2013;38(12):799–805.CrossRefGoogle Scholar
  4. 4.
    Shaw AT, Engleman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105–11.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–82.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Dziadziuszko R, Jassem J. Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer. J Thorac Oncol. 2013;8(12):1465–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Awad MM, Sahaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12:429–39.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Dhillon S, Clark M. Ceritinib: first global approval. Drugs. 2014;74(11):1285–91.PubMedCrossRefGoogle Scholar
  10. 10.
    Chugai Pharmaceutical Co Ltd. Alecensa® (alectinib): Japanese prescribing information. Tokyo: Chugai Pharmaceutical Co Ltd; 2014.Google Scholar
  11. 11.
    Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Latif M, Saeed A, Kim SH. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Arch Pharm Res. 2013;36(9):1051–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014;351:215–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74:1023–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Ou S-HI, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9:549–53.CrossRefGoogle Scholar
  17. 17.
    Tanimoto A, Yamada T, Nanjo S, et al. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014;5:4920–8.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14(7):590–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Nakagawa K, Hida T, Seto T, et al. Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study [abstract no. 8103 plus poster]. J Clin Oncol. 2014;32(5 Suppl).Google Scholar
  20. 20.
    Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119–28.PubMedCrossRefGoogle Scholar
  21. 21.
    Ou S, Gadgeel S, Chiappori A, et al. Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028) [abstract]. Eur J Cancer. 2013;49:S19.Google Scholar
  22. 22.
    Tamura T, Seto T, Nakagawa K, et al. Updated data of a phase I/II study (AF-001JP) of alectinib, a CNS-penetrant, highly selective ALK inhibitor in ALK-rearranged advanced NSCLC [abstract no. 10]. In: Multidisciplinary Symposium in Thoracic Oncology, Chicago (IL); Oct 30–Nov 1 2014.Google Scholar
  23. 23.
    Seto T, Hida T, Nakagawa K, et al. Anti-tumour activity in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study [abstract no. 1224O]. In: European Society for Medical Oncology. Madrid; Sep 2014. p. 26–30.Google Scholar
  24. 24.
    Toyokawa G, Seto T. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? Clin Lung Cancer. 2014;15:313–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations